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AbstrACt
Objectives People who are marginalised (medically 
underserved) experience significant health disparities 
and their voices are often ‘seldom heard’. Interventions to 
improve professional awareness and engagement with these 
groups are urgently needed. This study uses a co-production 
approach to develop an online digital educational intervention 
in order to improve pharmacy staffs’ intention to offer a 
community pharmacy medication review service to medically 
underserved groups.
Design Before/after (3 months) self-completion online 
questionnaire.
setting Community pharmacies in the Nottinghamshire 
(England) geographical area.
Participants Community pharmacy staff.
Intervention Online digital educational intervention.
Primary and secondary outcome measures The primary 
outcome measure was ‘behaviour change intention’ using a 
validated 12-item survey measure. The secondary outcome 
measure was pharmacist self-reported recruitment of 
underserved groups to the medication review service.
results All pharmacies in the Nottinghamshire area (n=237) 
were approached in June 2017 and responses were received 
from 149 staff (from 122 pharmacies). At 3 months (after 
completing the baseline questionnaire), 96 participants (from 
80 pharmacies) completed a follow-up questionnaire, of 
which two-thirds (n=62) reported completing the e-learning. 
A before/after comparison analysis found an improving 
trend in all the five constructs of behaviour change intention 
(intention, social influence, beliefs about capabilities, moral 
norms and beliefs about consequences), with a significant 
increase in mean score of participants’ ‘beliefs about 
capabilities’ (0.44; 95% CI 0.11 to 0.76, p=0.009). In the 
short-term, no significant change was detected in the 
number of patients being offered and the patient completing 
a medication review.
Conclusions Although increases in the numbers of patients 
being offered a medication review was not detected, the 
intervention has the potential to significantly improve 
pharmacy professionals’ 'beliefs about capabilities' in 
the short-term. Wider organisational and policy barriers 
to engagement with marginasied groups may need to be 
addressed. Future research should focus on the interplay 
between digital learning and practice to better identify and 
understand effective practice change pathways.
IntrODuCtIOn
The right to physical and mental health is 
a universal human right.1 However, in prac-
tice, vulnerable people, particularly those 
strengths and limitations of this study
 ► To our knowledge, this is the first study investigat-
ing the impact of a co-produced digital educational 
intervention for pharmacy professionals to improve 
the offer of a pharmacy medicine management to 
marginalised groups.
 ► Out of the original sample, 33 pharmacies declined 
to take part in the study. It is not known whether 
there were perceived barriers to e-learning or in-
stitutional indifference to addressing inequities in 
health.
 ► It is unknown whether participants completed the 
e-learning as intended or to what extent the digi-
tal learning accommodated different learning 
preferences.
 ► It is also unclear whether professional ‘belief about 
capabilities’ were sustained beyond 3 months.
 ► This study relied on self-reports of intention mea-
sures, as well as the number of patients engaged, 
so the actual recruitment and engagement with the 
underserved communities are not known.
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belonging to marginalised or ‘medically underserved’ 
groups (eg, people with disabilities; people from black, 
Asian and minority ethnic backgrounds; the homebound; 
the homeless; and people with mental illness), can often 
face significant obstacles to receiving even basic health-
care.2 3 Consequently, they experience higher rates of 
disease and ill-health and find accessing and navigating 
health and screening services more challenging when 
compared with the general population.3–6
Research indicates that people from medically under-
served groups encounter poorer patient-professional 
communication7 and sometimes racism or cultural 
bias.8 9 They also have been found to hold strong beliefs 
that they cannot be helped,10 face discrimination or 
disempowerment because of their circumstance,11 and 
are disenfranchised from mainstream primary health-
care.12 Inequitable access to routine or preventative care 
risks higher rates of emergency admissions13 and conse-
quently increases pressure on emergency care services.14 
Addressing inequitable access to health services is a key 
priority for the UK National Health Service (NHS).15
Strategies using co-production to address health 
inequalities have received growing professional and polit-
ical attention in light of a changing patient–provider rela-
tionship that sees patients more as ‘partners’ rather than 
passive recipients of healthcare.16 The co-production 
concept could be well placed to improve services to medi-
cally underserved groups as it acknowledges the value of 
people’s ‘lived experience’ and recognises that people 
are well placed to advise on how best services could make 
a positive difference to their lives.17 Alongside tailoring 
to patient preferences, the process also acknowledges 
the input and expertise of front-line healthcare staff.18 
Involving patients in service improvement has been 
suggested to help improve the quality of services delivered 
and helps redress inequities in service accessibility.19 20 In 
addition, there is growing literature demonstrating the 
positive outcome of co-produced e-learning materials 
designed to improve health professionals’ awareness and 
confidence to deliver care to vulnerable groups.21 22
We hypothesised that a co-produced digital educational 
intervention might improve pharmacy professionals’ 
awareness and engagement with medically underserved 
groups. This study therefore aimed to evaluate whether 
such an intervention could improve staff intention to 
engage with marginalised groups. Our study also sought 
to measure any impact this may have on the actual provi-
sion (numbers of MURs) offered to people who are medi-
cally underserved.
the English Medicine use review (Mur) service
The ‘MUR’ service, funded by the NHS,23 was commis-
sioned in England and Wales in 2005 and is free to patients. 
The service seeks to establish a picture of the patient’s 
medicine use, supports knowledge and understanding 
of therapy and adherence to treatment. Through this, it 
aims to resolve medicine-related problems and to address 
medicine-related concerns to reduce avoidable waste.24 
The service is organised as a one-to-one consultation and 
offered to patients annually. Pharmacists therefore have 
opportunities to hold detailed, private ‘sit down’ discus-
sions with the patient. These differ from the more routine, 
limited and brief ‘shop floor’ counselling encounters that 
occur at the time when medicines are handed to patients.
The NHS provides a fee of £28 for each review 
performed, with the total number each pharmacy 
contractor can claim to be subject to a cap of 400 annu-
ally. Pharmacists must be accredited through additional 
training, demonstrating nationally set competencies, 
before they offer the service.25 Pharmacy support staff 
are often involved with identifying eligible patients for 
MURs during the routine labelling and assembling of 
the patients’ medicines and at times offer the service to 
patients. However, they are not required and often do not 
receive formal training about the service.26
Early MUR evaluative work identified significant vari-
ability in its delivery, raising questions over their value 
in improving medicine use.27 28 The annual cap of 400 is 
often cited as a ‘target’ resulting in pharmacists reports of 
feelings pressurised due to a commercial ‘quantity driven’ 
culture.29 30 Consequently, pharmacists appear to invite 
patients who are either more amenable to the service or 
who are taking simpler medicine regimes. Although this 
may lead to patients being recruited easily and their MUR 
performed conveniently, those with more complex needs 
may be overlooked.29 30 As a result, some groups, partic-
ularly those who may already be medically underserved, 
may not be offered or may not have access to MURs as 
often as others.28–30
In attempts to improve the perceived value of MURs, 
service reforms were made in 2011. These changes spec-
ified ‘at-risk’ patient groups from which pharmacists 
should seek to recruit, for example, patients receiving 
high-risk medicines (eg, anticoagulants and diuretics), 
those with respiratory disease or if they have recently 
been discharged from the hospital.31 Despite moves to 
encourage the offer and uptake from these at-risk groups, 
there are still no requirements to recruit people who are 
marginalised and from medically underserved groups. 
Over three million MURs conducted in 2017–2018 and 
over 90% of all pharmacies in England now offering 
the service.32 Given recent moves to decommission the 
service, there is a strong case to develop interventions 
to reinforce a value-based healthservice, to focus NHS 
resources to those who need them the most and to make 
services more equitable.33
MEthODs
Patient and public involvement (PPI)
Several patient support groups were consulted, which 
shaped the study’s research questions, methodology and 
design. These included Healthwatch Nottingham (part 
of Healthwatch England, which promotes local voices 
in order to influence the delivery and design of health 
services); The Wayfarer Trust (education institute that 
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runs courses and public events for the Southeast Asian 
Muslim community); and The Himma Institute (a grass-
roots community charity providing services to vulnerable 
people).
An advisory panel for the study was formed, comprising 
two PPI representatives, who themselves identified with 
being from an underserved community. The panel met 
regularly to advise and challenge where necessary, on the 
study protocol, information to participants and on the 
digital educational intervention. There was also extensive 
involvement with patients from marginalised groups in 
the development of the digital educational intervention.
Digital educational intervention
Through their ease of accessibility, cost-effectiveness 
and learner flexibility and interactivity, digital learning 
interventions have been identified for delivering health 
professional training and improving health-related 
behaviours.34 35 Learning policies and professional educa-
tors have identified digital learning interventions as an 
effective delivery mechanism to ensure healthcare profes-
sional training is relevant and flexible enough to take into 
account different learning preferences.36–38
The digital learning intervention used in this study took 
the form of a series of three ‘Reusable Learning Objects’ 
(RLOs). RLOs are small, pedagogically designed, 'bite-
sized' chunks of learning that focus on a specific topic.22 
The contents included both visual illustration (eg, 
videos), interactivities and self-assessments. The interven-
tion was hosted on an online platform accessible online 
(https://www. nottingham. ac. uk/ helmopen/ rlos/ phar-
macy/ practice/ under- served/). The resource consists of 
three ROLs that focused on (1) Discovering underserved 
communities, (2) Exploring medicine experiences and 
developing empathy, and (3) Effectively interacting and 
engaging patients.
The resource was developed through a process of 
co-production. This involved informative semistructured 
interviews with patients (from marginalised groups) 
and pharmacy staff, alongside mixed patient–profes-
sional workshops. Interviews and workshops first sought 
to reveal patient stories of belonging to a marginalised 
community. Then experiences of how they manage 
medicines were elicited, and finally, strategies that phar-
macy staff could use to further engage with them were 
discussed. To improve face validity, the digital learning 
resource and study questionnaire were piloted on 10 
pharmacy students from the University of Nottingham. 
Only very minor changes to the questionnaire were made 
to improve readability. Full details of the development of 
the digital learning have been reported elsewhere.33 39
study design
This interventional study used a before/after comparison 
design and was conducted in Nottinghamshire, England, 
commencing in June 2017. Full details of the proposed 
protocol have been published elsewhere.33
Study participants were recruited from community phar-
macies and to reduce bias, all pharmacies in the Notting-
hamshire geographical area were included. Community 
pharmacy professionals (pharmacists and supporting 
staff) who were willing to complete online questionnaires 
and who were deemed to have ‘active’ involvement with 
the MUR service were invited. ‘Active involvement’ was 
defined as being involved with the process of identifying, 
inviting or undertaking MURs on a day-to-day basis.
After permission was sought from head offices or 
pharmacy owner/managers, an information sheet and 
invitation letter were sent via post to each pharmacy 
that provided the MUR service. At baseline, the online 
questionnaire was open for 4 weeks. Participants who 
completed the baseline questionnaire were given access 
to the digital learning intervention. Participants were 
offered a £25 gift voucher as an inconvenience allowance 
for them to complete the surveys; consent to take part was 
implied through their completion. To assess the impact 
of the intervention alone, no incentives were provided for 
participants to complete the digital learning.
To encourage participation, in addition to the postal 
invitation, pharmacies were contacted up to three 
times in this period by email or phone to invite them to 
complete the questionnaire. A follow-up questionnaire 
was then sent to participants 3 months after they were 
able to access the digital learning materials. To maximise 
the response rate, three reminders were sent via email or 
by telephone.
Data collection
The questionnaire survey was conducted using the Bristol 
Online Survey system (https://www. onlinesurveys. ac. 
uk/). Characteristics of participants, including demo-
graphics, that is, age, gender, educational achievement 
and details of any previous MUR training received; char-
acteristics of their pharmacies, such as ownership type (ie, 
large multiples/supermarket), were initially collected. 
They were then granted access to the digital learning. 
Kirkpatrick’s Evaluation Model was used as a framework 
to guide data collection.40 This model is based on four 
levels. The first two assess learner satisfaction and change 
in knowledge or attitude with the training resource. The 
study aimed to go beyond these to detect higher order 
changes in levels 3 and 4. The third level describes the 
changes in behaviour brought about by the training, with 
the final level measuring the application of the partici-
pants’ learning to their practice.
The extent of participants’ behaviour change intention 
(Kirkpatrick’s level 3) was assessed by a Continuing Profes-
sional Development (CPD) Reaction Questionnaire. The 
CPD Reaction Questionnaire is a 12-item theory-based 
instrument (online supplementary appendix 1) grounded 
in the theory of planned behaviour and Triandis theory.41 
It is a validated and reliable tool with robust metric prop-
erties which has been used to assess the impact of CPD 
activities on health professionals' behaviour intentions 
in clinical practice. The 12-item measure was used to 
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Figure 1 Flowchart of the study process.
compute five constructs relating to behaviour change 
intention, namely, (1) intention, (2) social influence, (3) 
beliefs about capabilities, (4) moral norm and (5) beliefs 
about consequences. Data were also collected on the 
effect of the CPD on the number of MURs performed on 
medically underserved groups (Kirkpatrick’s fourth level) 
before and after the intervention.
Pharmacists were also asked to record at baseline and at 
3 months the number of patients they had recruited from 
medically underserved groups over the previous 4 weeks. 
To facilitate recording, the following list of common 
medically underserved groups was provided:
 ► People with disability (eg, physical, visual, hearing 
and learning).
 ► People who are who are homebound.
 ► People from Black, Asian and Minority Ethnic 
(BAME) communities.
 ► People with mental health illness.
 ► People from the lesbian, gay, bisexual, transgender 
and queer (LGBTQ) communities.
 ► People from the traveller community, people who 
are homeless, or people who are refugees or seeking 
asylum.
 ► Older people with multiple illnesses and many (>12) 
medicines.
 ► People from any other medically underserved 
community.
sample size
A sample size of approximately 60 participants (paired 
before/after data) was needed to provide 80% power to 
detect a mean change of 0.44 (behaviour change inten-
tion) or greater, assuming the SD is 1.2.
Data analysis
Descriptive statistics were used to summarise demo-
graphics and characteristics. Continuous data were 
presented using means and SD if approximately normally 
distributed and medians and IQR if non-normally distrib-
uted. Categorical data were described using frequencies 
and percentages.
To assess the effect of the digital learning, baseline scores 
were compared with follow-up data, which were collected 
after the intervention period. The changes between the 
baseline and follow-up test scores were analysed using 
t-tests if they were found to be normally distributed, and 
the mean difference and 95% CI were presented. It has 
been suggested that t-tests are appropriate tests and can 
be used where responses are recorded on a Likert scale.42 
Statistical significance was assessed at the 5% (two-sided) 
level. All statistical analyses were conducted using IBM 
Statistical Package for Social Sciences (SPSS) V.24.43
rEsults
recruitment of pharmacies and participants
All of the 237 community pharmacies within the Notting-
hamshire area were approached to take part in the 
study. Three pharmacies were ineligible as they were not 
providing the MUR service, and 33 pharmacies declined 
to take part due to them being ‘too busy’, being ‘short 
staffed’, not having ‘enough time’ to complete the 
learning or questionnaire, or were ‘not interested’. One 
supermarket chain declined to give permission to contact 
their pharmacies because they had ‘other educational 
priorities’ for their pharmacies.
Baseline questionnaire responses (n=149 participants) 
were received from 122 out of the 201 pharmacies who 
initially expressed an interest in taking part in the study 
(response rate=61%). Further to this, 100 participants 
(67%) from 80 pharmacies completed the follow-up 
questionnaire. After excluding two of the 100 partic-
ipants who had no baseline survey (follow-up question-
naire link mistakenly forwarded by a work colleague) and 
a further two that were found to have duplicate records 
of the follow-up survey, the adjusted follow-up participant 
response rate was 64% (96/149) (figure 1).
Characteristics of recruited pharmacies and participants
The profile of pharmacies that completed the follow-up 
questionnaire was found to be similar to those completing 
the baseline survey, suggesting there was no influence 
by pharmacy type (table 1). Most pharmacies reported 
being part of a multiple or classed as an independent, 
with almost a fifth being co-located within a general prac-
tice. Approximately three-quarters of the pharmacies had 
a single pharmacist on duty with most dispensing between 
100 and 400 prescriptions items per day.
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Table 1 Comparing the characterises of pharmacies 
between the baseline survey with the follow-up survey
Characteristics
Baseline (n=122 
pharmacies) (%)
Follow-up (n=80 
pharmacies) (%)
Type of pharmacy
  A multiple/part of 
a chain
75 (61.5) 48 (60.0)
  An independent 40 (32.8) 26 (32.5)
  A supermarket 6 (4.9) 5 (6.3)
  Other 1 (0.8) 1 (1.3)
Co-location within a general practice
  No 100 (82.0) 64 (80.0)
  Yes 20 (16.4) 15 (18.8)
  Don’t know/
unsure
2 (1.6) 1 (1.3)
Pharmacists on duty in the dispensary on a typical day
  A single 
pharmacist
91 (74.6) 56 (70.0)
  Two pharmacists 27 (22.1) 20 (25.0)
  Three pharmacists 4 (3.3) 4 (5.0)
Average number of prescription items dispensed on a 
typical day
  Less than 100 3 (2.5) 3 (3.8)
  101–200 26 (21.3) 20 (25.0)
  201–300 22 (18.0) 13 (16.3)
  301–400 28 (23.0) 18 (22.5)
  401–500 13 (10.7) 8 (10.0)
  500 plus 5 (4.1) 2 (2.5)
  I don’t know/
unsure
  Not reported
8 (6.6)
17 (13.9)
6 (7.5)
10 (12.5)
Approximately half of the 149 participants were female 
(47%), with a mean age of 37 years. The majority (81%) of 
participants were pharmacists, with the remainder being 
dispensers, medicine counter assistants, non-pharma-
cist managers and preregistration pharmacists (table 2). 
Most of the participants reported having been in their 
role for 1–5 years (34%) and having worked on average 
31–40 hours per week (44%). Two-thirds of respondents 
(65%) reported having attempted part of or all the digital 
learning. Of those who did not complete the resource, 
the most common reason provided was that they did not 
have enough time or that the topic of the learning mate-
rial was not perceived as necessary (table 2).
Concerning the 120 pharmacists, most respondents 
were either the pharmacy manager (32%) or the branch 
manager (29%) or described themselves as an employee 
pharmacist (27%). Almost half (43%) reported being 
qualified as a pharmacist for 10 years or less and a quarter 
between 11 and 20 years. Forty-one per cent of pharma-
cists had been accredited to perform MURs for more 
than 10 years with most (72%) not having undertaken 
any further MUR training since accreditation (table 3).
Primary outcome: behaviour change intention
When scores were compared between the five constructs 
of ‘behaviour change intention’ (baseline vs the end of 
follow-up), it was found that from the total of 96 partici-
pants who had completed both questionnaires, the mean 
difference of scores improved. However, there was no 
statistically significant results found between the differ-
ences of mean scores before and after the intervention 
period (table 4).
In the subgroup of the 62 participants who reported 
completing the digital learning, the improvement of 
mean difference of the five constructs before and after 
the intervention period was found to be higher than that 
of the total 96 participants (table 4). There was a statically 
significant increase in the construct relating to beliefs 
about capabilities; the mean difference was 0.44 (95% CI 
0.11 to 0.76, p=0.009). No statistically significant differ-
ences were observed on the other four constructs.
secondary outcome: self-reported recruitment of medically 
underserved groups to the Mur service
Pharmacists were asked to report the total number of 
MURs undertaken within the last 4 weeks and how many 
of these patients were from medically underserved groups. 
The before/after comparison analysis did not detect a 
statistical significance difference between both within the 
total sample and the subsample who had completed the 
digital learning (table 5).
DIsCussIOn
Main findings
This study found that a digital educational intervention 
has the potential to positively influence pharmacy profes-
sionals’ ‘beliefs about capabilities’ construct of behaviour 
change intention. This construct achieved statistical 
significance, suggesting a possible improvement in profes-
sionals’ confidence to interact and engage people from 
marginalised communities. There was a lack of statistical 
significance observed for the other four constructs.
The reported high baseline scores for ‘intention’, 
‘moral norms’ and ‘beliefs about consequences’ may 
have been influenced by social desirability or approval 
bias.44 This may have resulted in a ceiling effect, which 
meant differences in scores before and after the interven-
tion could not be detected. Given the behaviour being 
measured was ‘actively engaging with or inviting patients 
who are underserved for an MUR’, respondents may 
have been inclined to score themselves highly at baseline 
because they felt this was the right or ethical thing to do. 
The final construct ‘social influence’ relates to how the 
respondents’ peers are perceived. It is well known that 
pharmacists often feel a notion that there is frequently 
organisational pressure to undertake MURs resulting in 
many feeling the service is consequently inefficacious or 
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Table 2 Comparison of the characteristics of participants who completed the baseline survey with those completing the 
follow-up survey
Characteristics Category Baseline (n=149) (%) Follow-up (n=96) (%)
Gender Male 78 (52.3) 53 (55.2)
Female 70 (47.0) 43 (44.8)
Transgender 1 (0.7) –
Mean age Mean (SD) (years) 36.7 (11.0) 37.6 (11.4)
Not reported 3 1
Job role Non-pharmacist manager 4 (2.7) 4 (4.2)
Preregistration pharmacist 5 (3.4) 1 (1.0)
Medicines counter assistant/
dispenser
20 (13.4) 13 (13.5)
Pharmacists 120 (80.5) 78 (81.3)
Average number of hours worked Up to 20 hours a week 6 (4.0) 4 (4.2)
21–30 hours a week 19 (12.8) 14 (14.6)
31–40 hours a week 65 (43.6) 38 (39.6)
Over 41 hours a week 59 (39.6) 39 (40.6)
Not reported – 1 (1.0)
How long the participant has worked at 
the pharmacy
Less than a year 27 (18.1) 9 (9.4)
1–5 years 51 (34.2) 41 (42.7)
6–9 years 30 (20.1) 18 (18.8)
10 or more years 33 (22.1) 26 (27.1)
Don’t know/not sure – 1 (1.0)
Not reported 8 (5.4) 1 (1.0)
Approximate number of years in current 
role
Less than a year 23 (15.4) 12 (12.5)
1–5 years 58 (38.9) 35 (36.5)
6–9 years 29 (19.5) 24 (25.0)
10 or more years 39 (26.2) 25 (26.0)
Highest educational achievement Masters pharmacy degree/other 
Masters’ degree
90 (60.4) 51 (53.1)
Undergraduate degree 25 (16.8) 22 (22.9)
General Certificate of Secondary 
Education/National Vocational 
Qualification/Advanced Level 
(GCSE/NVQ/A level)
19 (12.8) 11 (11.5)
Postgraduate clinical diploma 12 (8.1) 11 (11.5)
PhD 3 (2.0) 1 (1.0)
Attempted part of or all the digital 
learning
Yes – 62 (64.6)
No – 34 (35.4)
Reason for not attempting the digital 
learning
Did not have enough time to do 
the learning
– 18 (52.9)
Did not feel the learning was 
necessary
– 6 (17.6)
Do not know/unsure – 5 (14.7)
Did not receive or could not 
access the learning
– 3 (8.8)
Other (change to a non-customer 
facing role)
– 2 (5.9)
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Table 3 Subgroup comparison of the characteristics of pharmacist participants who completed the baseline survey with 
those completing the follow-up survey
Pharmacists Category
Baseline (n=120) 
(%)
Follow-up (n=78) 
(%)
Details of pharmacists Pharmacist and pharmacy manager 38 (31.7) 26 (33.3)
Pharmacist and branch manager 35 (29.2) 16 (20.5)
Employee pharmacist 32 (26.7) 28 (35.9)
Locum pharmacist 14 (11.7) 6 (7.7)
Superintendent pharmacist 1 (0.8) 2 (2.6)
Number of years qualified as a 
pharmacist
1–10 years 51 (42.5) 33 (42.3)
11–20 years 30 (25.0) 19 (24.4)
21–30 years 17 (14.2) 13 (16.7)
31 to 40 years 11 (9.2) 7 (9.0)
41 to 50 years 2 (1.7) 2 (2.6)
Other 9 (7.5) 4 (5.1)
Year accredited to perform MURs 2005–2007 49 (40.8) 36 (46.2)
2008–2010 17 (14.2) 13 (16.7)
2011–2013 31 (25.8) 14 (17.9)
2014–2016 19 (15.8) 10 (12.8)
2017 2 (1.7) 2 (2.6)
Not reported 2 (1.7) 3 (3.8)
Further MUR training undertaken* No 86 (71.7) 65 (83.3)
Yes 32 (26.7) 11 (14.1)
Not reported 2 (1.7) 2 (2.6)
Type of further MUR training 
undertaken
Centre for Pharmacy Postgraduate Education/
The National Pharmacy Association/Company 
Chemists’ Association
14 (43.8) 2 (18.2)
Self-directed learning (ie, pharmacy articles, 
diploma and specific training days)
14 (43.8) 4 (36.4)
Employer training 4 (12.5) 2 (18.2)
Not specified – 3 (27.3)
*At the baseline, the participants were asked about any MUR training undertaken since their MUR accreditation; at the follow-up survey, 
participants were asked about any MUR training taken in the past 3 months.
MUR, Medicines Use Review.
suboptimal.29 30 This view may explain the lack of change 
with this construct.
When recruitment from medically underserved groups 
was examined, statistical differences were not detected at 
3 months. There are several practice-based barriers that 
may have made recruitment from these groups more 
challenging. First, there is currently no financial incen-
tives to offer the service to such groups that are deemed 
‘hard to reach’. For example, there may have been a lack 
of available resources to provide translation services or 
a lack of staffing to allow pharmacists to undertake visits 
to people who are homebound.45 Second, there were 
low numbers of front-line pharmacy support staff partici-
pating in the study, suggesting either lack of interest with 
the subject or difficulty for the pharmacist-in-charge to 
adequately engage staff or provide them time to complete 
the training. With support staff routinely being involved 
in offering and recruiting patients for MURs, it may 
have been challenging for pharmacists to enable change 
without them also completing the digital learning. Third, 
from a patient perspective, there is evidence that phar-
macy services are generally poorly understood and that 
engagement and understanding of their value are varied 
or conflicting, with consequences for framing and sense-
making.46 These challenges may have been greater 
given medically underserved groups are not routinely 
approached or engaged with such services.39 Time may 
be needed for such marginalised groups to become accus-
tomed to be offered services from the pharmacy.
Other more methodological reasons why there was no 
detected increase in numbers may have been because of 
the challenges in identifying patients belonging to these 
groups (eg, people from the LGBTQ community) or the 
infrequency in which they present at the pharmacy (eg, 
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Table 4 Before/after subgroup comparison of the mean score for the five constructs of ‘behaviour change intention’ between 
the baseline and the end of follow-up
Construct variable Summary measure Baseline Follow-up Mean difference (95% CI) P value
Participants completed baseline and follow-up survey (n=96)
  Intention (n=96) Median (IQR) 5.50 (2.00) 5.75 (2.00) 0.22 (−0.07 to 0.51) 0.140
  Social influence (n=96) Mean (SD) 4.21 (1.26) 4.28 (1.26) 0.07 (−0.19 to 0.33) 0.578
  Beliefs about capabilities 
(n=95*)
Mean (SD) 5.39 (1.20) 5.61 (1.02) 0.22 (−0.02 to 0.47) 0.067
  Moral norm (n=92*) Median (IQR) 6.50 (1.50) 6.50 (1.38) 0.21 (−0.04 to 0.45) 0.101
  Beliefs about 
consequences (n=96)
Mean (SD) 5.96 (1.09) 6.08 (0.99) 0.13 (−0.10 to 0.35) 0.279
Subgroup participants: completed baseline and follow-up survey and the digital learning (n=62)
  Intention (n=62) Median (IQR) 6 (2.50) 6 (2.00) 0.36 (−0.26 to 0.75) 0.067
  Social influence (n=62) Mean (SD) 4.30 (1.28) 4.56 (1.12) 0.26 (−0.04 to 0.56) 0.085
  Beliefs about capabilities 
(n=61*)
Mean (SD) 5.39 (1.30) 5.83 (1.03) 0.44 (0.11 to 0.76) 0.009†
  Moral norm (n=60*) Median (IQR) 6.5 (1.50) 7.0 (1.00) 0.29 (−0.02 to 0.61) 0.070
  Beliefs about 
consequences (n=62)
Mean (SD) 6.05 (1.12) 6.21 (0.93) 0.16 (−0.13 to 0.45) 0.271
Means are reported where the data are normally distributed.
*Missing construct values.
†Statistically significant difference.
people who are homeless). A large-scale trial is needed 
to ensure sufficient people are recruited to detect differ-
ences. It is also not known whether a different outcome 
may have resulted if respondents could choose to under-
take the digital educational intervention at a time that 
was convenient to them.
Implications
Medication review services has seen significant recon-
figuration and investment in light of patient widespread 
problems taking medicines47 attributed to concerns 
about dependency, tolerance and side effects.48 49 The 
community pharmacist workforce is increasingly being 
deployed, predominantly in developed countries, to 
promote effective use of medicines.50 51 However, there 
remains significant challenges to ensure equitable access 
to these services.
This study has several important implications for phar-
macy organisations, educationalists and policymakers. To 
target more vulnerable groups (who may benefit most 
from an intervention), there is a need to redress concerns 
over the lack of perceived effectiveness and cost-effective-
ness of MURsand this could represent an opportunity to 
enhance professional status.52 For educationalists and 
those offering CPD courses, the co-production approach 
could ensure greater patient involvement and promote 
their unique perspective and preferences. Alongside this 
educational intervention, policymakers may wish to recon-
sider more funding to encourage scope for future devel-
opment. In one evaluative study by Latif and colleagues, 
making additional service costs available to pharmacies to 
deliver MURs to vulnerable homebound patients poten-
tially led to a reduction in hospital admissions.53
Future research should consider the broader influ-
ence that public engagement and health promotion 
campaigns have at engaging marginalised communities 
in health services. Strategies are also needed to develop 
policy reforms to ensure people have more equitable 
access to care and how system-wide quality improvements 
can be achieved to proactively increase engagement with 
communities perceived as being ‘hard to reach’.54
strengths and limitations
To our knowledge, this is the first study attempting to 
triangulate findings from self-reported pharmacy profes-
sionals’ behaviour change intention and to assess this 
alongside actual changes in practice. The co-produced 
intervention sought to include views of both patients and 
professionals, and the digital format was a feasible means 
of delivery to pharmacy professionals. There were good 
baseline responses from pharmacies (61%), which may 
have been due to the £25 gift voucher incentive, which 
was made available to participants. However, there were 
approximately one-third of respondents who did not 
complete the follow-up questionnaire, and this could 
have potentially skewed the results. Out of the original 
sample, 33 pharmacies declined to take part in the study, 
and out of the 149 participants who completed the base-
line questionnaire, just over 40% reported completing 
the digital learning. The extent to which these numbers 
reflect barriers to learning or institutional indifference 
to the issue is not known. Furthermore, this study was 
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Table 5 A subsample before/after comparison of the pharmacist-reported number of MURs with medically underserved 
groups
Number of MURs 
undertaken over the last 4 
weeks Summary measure Baseline Follow-up Mean difference (95% CI) P value
Respondents from participants completed baseline and follow-up survey
Total number (n=74) Mean (SD) 20.8 (15.35) 21.3 (17.18) 0.49 (−2.66 to 3.65) 0.756
With disability (physical, 
visual, hearing and learning)
Median (IQR) 1.0 (2.0) 2.0 (2.0) −0.12 (−0.50 to 0.47) 0.956
Who are homebound Median (IQR) 1.0 (0.0) 1.0 (0.0) 0.14 (−0.10 to 0.37) 0.254
From black, Asian and 
minority ethnic communities
Median (IQR) 2.0 (3.0) 2.5 (2.0) 0.35 (−0.09 to 0.79) 0.114
With mental health illness Median (IQR) 2.0 (2.0) 2.0 (3.0) 0.03 (−0.51 to 0.56) 0.920
From the lesbian, gay, 
bisexual, transgender and 
queer communities
Median (IQR) 1.0 (0.0) 1.0 (1.0) 0.23 (−0.01 to 0.47) 0.065
The traveller community/
homeless/refugees or 
seeking asylum
Median (IQR) 1.0 (0.0) 1.0 (0.0) 0.14 (−0.12 to 0.39) 0.289
Who are older with multiple 
illnesses and many (>12) 
medicines
Median (IQR) 4.0 (6.0) 4.5 (7.0) 0.39 (−0.31 to 1.09) 0.267
From any other medically 
underserved community
Median (IQR) 1.0 (0.0) 1.0 (1.0) −0.01 (−0.49 to 0.47) 0.955
espondents from participants completed the baseline and follow-up surveys, and the digital learning
Total number (n=44) Mean (SD) 25.2 (16.50) 25.2 (19.25) −0.02 (−4.97 to 4.93) 0.993
With disability (physical, 
visual, hearing and learning)
Median (IQR) 2.0 (2.0) 2.0 (2.0) 0 (−0.71 to 0.71) 1.000
Who are homebound Median (IQR) 1.0 (0.0) 1.0 (0.0) 0.05 (−0.11 to 0.21) 0.570
From black, Asian and 
minority ethnic communities
Median (IQR) 3.0 (4.0) 3.0 (4.0) 0.43 (-0.23 to 1.09) 0.194
With mental health illness Median (IQR) 2.0 (3.0) 2.0 (4.0) 0.20 (−0.58 to 0.98) 0.600
From the lesbian, gay, 
bisexual, transgender and 
queer communities
Median (IQR) 1.0 (0.0) 1.0 (1.0) 0.23 (−0.14 to 0.60) 0.222
The traveller community/
homeless/refugees or 
seeking asylum
Median (IQR) 1.0 (0.0) 1.0 (0.0) 0.32 (−0.06 to 0.70) 0.099
Who are older with multiple 
illnesses and many (>12) 
medicines
Median (IQR) 4.5 (7.0) 4.5 (7.0) −0.02 (−1.03 to 0.98) 0.964
From any other medically 
underserved community
Median (IQR) 1.0 (1.0) 1.0 (1.0) −0.09 (−0.77 to 0.59) 0.789
Only responses included where there are paired data.
MUR, Medicines Use Review.
conducted in one geographical region. It is unknown 
to what extent the sample population is representative 
of other areas or those pharmacies in that are in more 
remote locations.
There are several other limitations to this study. 
Regarding study design, this was a before and after study. 
As Grimshaw et al notes,55 although such designs are rela-
tively easy to conduct and are superior to observational 
studies, they can be intrinsically weak evaluative designs 
with non-randomisation making it difficult to attribute 
observed changes to the intervention. It is also unknown 
whether participants completed the digital learning 
as intended, to what extent the digital learning accom-
modated different learning preferences or whether any 
behaviour change intention was sustained beyond 3 
months.
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Regarding aspects of the digital resource which may 
have influenced participants beliefs about capabilities, 
we speculate that the final RLO called ‘effectively inter-
acting and engaging patients’ may have had the greatest 
impact, although we cannot be certain. Lastly, this study 
relied on self-reports of intention measures as well as the 
number of patients engaged, so the actual recruitment 
and engagement with the underserved communities is 
not known.
COnClusIOn
The co-produced digital educational intervention was 
shown to be effective at improving the perceived capabili-
ties of pharmacy professionals towards engaging with the 
medically underserved. However, this resource alone may 
not be sufficient to bring about actual practice change. 
Changes in the organisations and to the policy may also 
be needed to achieve meaningful engagement and trac-
tion with patients who belong to medically underserved 
groups. This study adds to the continued debate on how 
best we can make services more equitable in order to tackle 
health inequalities. In this respect, the study provides a 
novel approach and information on the feasibility of deliv-
ering the educational intervention to pharmacies. Future 
research should focus on the interplay between the agency, 
organisation and policy constructs to better identify and 
understand the barriers to effective practice change.
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